Feature | October 15, 2014

Imricor Announces First Procedures in Clinical Study of MR-Enabled Cardiac Ablation Products

Up to 15 patients will be enrolled in United Kingdom study

October 15, 2014 — Imricor Medical Systems, Inc. announced the first three cardiac ablation procedures were completed in the first clinical study that is evaluating the feasibility of their magnetic resonance (MR)-enabled products to treat atrial flutter. Prof. Reza Razavi, head of the Division of Imaging Sciences and Biomedical Engineering, King's College London, is the principal investigator for the study and performed the procedures along with Mark O'Neill, professor of cardiac electrophysiology and consultant cardiologist, Guy's and St. Thomas' NHS Trust in the United Kingdom, The prospective pilot study will enroll up to 15 patients at this center.

The Vision-MR Ablation Catheter and Advantage-MR EP Recorder/Stimulator System are currently being evaluated for the treatment of atrial flutter. The Vision-MR Ablation Catheter looks, feels and functions like a conventional ablation catheter. The Advantage-MR EP Recording/Stimulator System is also MR-enabled to avoid dangerous electromagnetic interactions with the MRI scanner and provide clear intra-cardiac electrograms and interference-free MR images. The system delivers the needed MR-enabled recording and pacing functions. Both products are used in conjunction with the iSuite image guidance platform that is provided by Philips.

"There have been many technical advances that have gone into this technology in order to create a system suitable for clinical use, and it has performed extremely well in the early phases of clinical trials. This is a groundbreaking study and we believe that there is a great future for MR-guided heart rhythm interventions. Not only is the requirement for X-rays removed, but for the first time the clinician is able to see the detailed anatomy of the heart, in real-time, during the procedure, and the therapeutic ablation lesions that have been created. The impact that such information could have on complex ablation procedures is enormous. We hope that this is a great step forward in the care and treatment of patients with abnormal heart rhythms," said Razavi.

For more information: www.imricor.com

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Overlay Init